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Pathophysiology of altered glomerular function in amino-
glycoside-treated rats. To evaluate the relative influences of gen-
tamicin and tobramycin on glornerular function, we studied three
groups of normal hydropenic rats. Group I had 8 rats that served
as controls. Group 2 had 9 rats that were given gentamicin (40
mg/kg of body wt per day for 10 days). Group 3 had 10 rats that
received tobraniycin instead of gentamicin. In addition, we at-
tempted to suppress angiotensin II (All) generation in two addi-
tional groups of rats and then study the glomerular response to
gentamicin: in 6 rats, isotonic sodium chloride was substituted
for tap water for drinking throughout the period of study (group
4), and in 7 other gentamicin-treated rats, captopril was given
orally (group 5). A sixth group received captopril alone (group
6). Following gentamicin treatment in group 2, values for single
nephron GFR (SNGFR) were markedly lower (21.7 2.1 nI/mm)
than they were in groups 1(35.7 1.4) or 3 (34.1 2.9). Declines
in whole kidney GFR in group 2 paralleled the fall in SNGFR.
Reduction in SNGFR with gentamicin was due both to a marked
decline in the glomerular capillary ultrafiltration coefficient, Kf,
and in the initial glomerular plasma flow rate, QA. With saline
administration (group 4), the decline in SNGFR was partially
blunted, whereas with captopril (group 5) the effects of gen-
tamicin on SNGFR, QA, and K1 were largely abolished. Morpho-
logic studies revealed no discernible glomerular defects in any
group, whereas proximal tubule damage was evident with both
aminoglycosides, irrespective of the state of the renin-angioten-
sin system. Thus, in the dosage used, gentamicin elicits greater
impairment in glomerular function than does tobramycin, and by
mechanism(s) that are at least partially responsive to suppression
of All generation.
Physiopathologie des modifications de Ia fonction glomérulaire
chez les rats traités par l'aminoglycoside. Afin d'évaluer les influ-
ences relatives de Ia gentamicine et de Ia tobramycine sur Ia
fonction glomérulaire trois groupes de rats normaux hydro-
péniques ont été étudiés. Groupe 1: 8 rats servant de contrôles.
Groupe 2: 9 rats traités par Ia gentamicine (40 mg/kg poids corpo-
rel/jour, voie intra-péritonéale, pendant 10 jours). Groupe 3: 10
rats ont recu de Ia tobramycine au lieu de gentamicine. Nous
avons, de plus, tenté de supprimer Ia génération d'angiotensine
II (All) dans deux autres groupes de rats, puis étudié Ia réponse
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glomérulaire a Ia gentamicine: chez 6 rats le chlorure de sodium
isotonique a été substitué a l'eau de robinet pendant toute la pé-
node d'étude (groupe 4), et chez 7 autres rats traités par La gen-
tamicine du captopril a été donné par voie orale (groupe 5). Un
sixième groupe a été traité par le captopril seul (groupe 6). A Ia
suite du traitement par la gentamicine dans le groupe 2 les va-
leurs des filtrations glomérulaire individuelles (SNGFR) ont été
nettement inférieures (21,7 1,2 nllmin) a celles obtenues dan
les groupes 1(35,7 1,4) ou 3 (34,1 2,9), La diminution du
debit de filtration global dans le groupe 2 est paralléle a celle de
SNGFR. La reduction de SNGFR par Ia gentamicine est due a Ia
fois a Ia diminution importante du coefficient d'ultrafiltration Ca-
pillaire, K1, et du debit plasmatique glomérulaire initial (QA). Au
cours de l'administration de le chlorure de sodium (groupe 4) Ia
diminution de SNGFR est en partie masquée alors qu'avee le
captopril (groupe 5) les effets de Ia gentamicine sur SNGFR, QA
et K1 sont abolis. Les etudes morphologiques ne montrent auc-
une lesion glomérulaire décelable dan les différents groupes
alors que les lesions tubulaires proximales sont évidentes avec
les deux aminoglycosides, indépendamment de l'Ctat du système
rénine-angiotensine. Ainsi, aux doses employees, la gentamicine
entrine une plus grande alteration de la fonction glomérulaire
que la tobramycine par un ou des méchanismes qui répondent au
moms partiellement a la suppression de la génération de All.
Given the importance of aminoglycoside antibiot-
ics in the clinical management of severe gram-nega-
tive infections, it is hardly surprising that consid-
erable effort has been directed toward an under-
standing of the potentially serious nephrotoxic side
effects that often accompany their use. In a recent
study from this laboratory, it was demonstrated that
gentamicin induces a dose-dependent decline in
whole kidney and single nephron GFR, due primari-
ly to a decline in the glomerular capillary ultrafiltra-
tion coefficient, K1 [1]. In view of results in several
animal studies [2-4] as well as in recent clinical
evaluations [5, 6] suggesting that tobramycin may
be less nephrotoxic than gentamicin, we under-
took to compare the effects of these aminoglyco-
sides on the functional and morphologic determi-
nants of glomerular ultrafiltration in the Munich-
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Wistar rat. In addition, because various models of
acute renal failure have been shown to be sensitive
to the renin-angiotensm and extracellular fluid vol-
ume status of the experimental animal [7—9], we
evaluated the separate influences of long-term high
salt intake and the oral angiotensin I converting en-
zyme inhibitor, captopril (SQ 14,225), on the neph-
rotoxic potential of gentamicin.
Methods
Micropuncture studies. Studies were performed
on 46 normal hydropenic adult Munich-Wistar rats,
each weighing 210 to 300 g. Six groups of rats were
studied. Group / had 8 normal hydropenic control
rats that were given daily i.p. sham-injections of
isotonic saline (0.25 ml) for 10 consecutive days.
Group 2 had 9 rats that were treated with gen-
tamicin sulfate (Garamycin® Schering Pharmaceu-
tical Corporation, Kenilworth, New Jersey) in a
dose of 40 mg/kg of body wt per day i.p. (0.20 to
0.30 ml) for 10 consecutive days. Group 3 had 10
rats that received tobramycin sulfate (Nebcin®, Eli
Lilly and Company, Indianapolis, Indiana) in a dose
of 40 mg/kg of body wt i.p. (0.20 to 0.30 ml) also for
10 consecutive days. Group 4 had 6 animals that
were given 0.9% sodium chloride solution sub-
stituted for tap water for 17 days. During the final 10
days, gentamicin was administered in a dose identi-
cal to that used in group 2. Group 5 had 7 animals
that were allowed to drink tap water, to which 0.5
mg/mi of captopril (SQ 14,225, o-2-niethyl-3-mer-
captopropanoyl-L-proline) was added for 3 days pri-
or to and for 10 days of gentamicin treatment, the
latter again in the same dose as that used in group 2.
The effectiveness of oral captopril to inhibit angio-
tensin II generation has been documented pre-
viously [10]. Group 6 had 6 animals that were
treated for 13 consecutive days with captopril
alone, in a dose identical to that used in group 5.
On the final day of the above treatment sched-
ules, rats were anesthetized with mactin (100 mg/
kg, i.p.), placed on a temperature-regulated micro-
puncture table, and subjected to tracheostomy.
Polyethylene catheters were inserted into the right
jugular vein for infusion of inulin and into the left
femoral artery for periodic blood sampling and esti-
mation of mean arterial blood pressure (AP). AP
was monitored with an electronic transducer (model
P23Db, Statham Instruments Division., Gould Inc.,
Hato Rey, Puerto Rico) connected to a direct-writ-
ing recorder (model 7712, Hewlett-Packard Co.,
Waltham, Massachusetts). The left kidney was pre-
pared for micropuncture in the same manner as de-
scribed previously [12].
Beginning 60 mm before micropuncture, the rats
received an i.v. infusion of isotonic sodium chloride
(0.9 mllhr). Inulin was present in a concentration of
7.5%, thereby resulting in a final plasma concentra-
tion of about 80 mg/dl. After this 60-mm equilibra-
tion period, exactly timed 1- to 2-mm samples of
fluid were collected from surface proximal con-
volutions from each of two or three nephrons for
determination of flow rate and inulin concentration
and calculation of single nephron glomerular filtra-
tion rate (SNGFR). The rate of fluid collection was
adjusted to maintain a column of polymer oil, three
to four tubule diameters in length in a relatively
constant position just distal to the site of puncture.
With the collection technique of controlled suction
validated for this laboratory [13], we produced
minimum changes in tubule diameter or the position
of the distal oil block. Coincident with these tubule
fluid collections, femoral arterial blood samples,
100 l in volume, were obtained for determination of
hematocrit and plasma inulin concentration. In
addition, two or three samples of urine from the
experimental kidney were collected for determina-
tion of flow rate and inulin concentration. For these
urine collections, indwelling (left) ureteral poly-
ethylene catheters (PE-lO) were used.
Hydraulic pressures were measured in single cap-
illaries within surface glomeruli by a continuously
recording, servonull micropipette-transducer sys-
tem. Micropipettes with outer tip diameters of 2 to 4
m and containing 2.0 M sodium chloride were
used. Hydraulic output from the servosystem was
channeled via an electronic transducer (Statham
model P23Db) to a second channel of the recorder.
Direct measurements of hydraulic pressure in single
glomerular capillaries (PGC), proximal tubules (PT),
efferent arterioles (PE), and third-order peritubular
capillaries (Pc) were recorded in each rat.
To obtain estimates of colloid osmotic pressure
(H) of plasma entering and leaving glomerular capil-
laries, we measured protein concentrations (C) in
femoral arterial (CA) and efferent arteriolar (CE)
blood plasma, as described previously [14]. CA was
taken as a measure of protein concentration in the
afferent arteriole. Colloid osmotic pressures were
calculated from these measured values of C using
the equation:
H = 1.63C + 0.294C2 (1)
These estimates of pre- and post-glomerular protein
concentration permitted calculation of the single
nephron filtration fraction (SNFF) and QA (see Eqs.
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3 and 4). From direct measurements of the decline
in hydraulic pressure along single afferent and ef-
ferent arterioles and estimates of blood flow through
these vessels, we calculated the vascular resis-
tances to blood flow through these individual ves-
sels (see Eqs. 7 through 9).
Analytical procedures. The volume of tubule
fluid collected from individual nephrons was esti-
mated from the length of the fluid column in a con-
stant-bore capillary tube of known internal diame-
ter. The concentration of inulin in the tubule fluid
was measured, usually in duplicate, by the micro-
fluorescence method of Vurek and Pegram [15]. In-
ulin concentration in plasma and urine was deter-
mined by the macroanthrone method of Führ,
Kaczmarczyk, and Krüttgen [16]. Protein concen-
trations in efferent artenolar and femoral arterial
blood plasmas were determined, usually in dupli-
cate, with an ultramicrocolorimeter by the method
of Viets et al [14].
Calculations. Single nephron glomerular filtra-
tion rate was calculated as
SNGFR = (TF!P)1 VTF (2)
where (TF/P)1 and VTF refer to the tubule fluid!
plasma inulin concentration ratio and the tubule
fluid flow rate, respectively.
Single nephron filtration fraction was derived
from the equation
SNFF = 1 — (CA/CE)
where CA and CE denote afferent and efferent arten-
olar plasma protein concentrations, respectively.
Initial glomerular plasma flow rate was calculated
as
QA = SNGFRJSNFF. (4)
Blood flow rate per single afferent arteriole or gb-
merulus was determined from the equation
GBF = QA/(1 — HctA) (5)
where HctA, the hematocrit of afferent arteriolar
blood, was considered to be equal to the femoral
arterial hematocrit.
Efferent arteriolar blood flow rate was derived
from the equation
EABF = GBF — SNGFR.
Resistance per single afferent arteriole was calcu-
lated as
RA = ([AP — PGC]IGBF)(7.962 x 10'°) (7)
where the factor 7.962 X 1O° was used to give resis-
tance in units of dyn sec cm5 when AP and PGC
were expressed in mm Hg and GBF in ni/mm.
Resistance per single efferent arteriole was deter-
mined from the equation
RE = ([P — P]/EABF)(7.962 x 1010). (8)
Total arteriolar resistance for a single pre- to
post-glomerular vascular unit was defined as
RTA = RA + RE. (9)
Finally, mean glomerular transcapillary hydraulic
pressure difference was calculated as
=
— PT. (10)
Morphologic studies. Morphologic studies, in-
cluding light microscopy and transmission and
scanning electron microscopy, were performed on
three animals in each group. After the conclusion of
the micropuncture studies, the kidneys of these ani-
mals were fixed by perfusion with 1.25% glutaralde-
hyde in 0.1 M cacodylate buffer (pH, 7.4) at 110 mm
Hg for 6 to 8 mm. For this purpose, the abdominal
aorta was cannulated near its bifurcation with a
polyethylene catheter (PE-160) connected to a res-
ervoir containing the fixative. Hepatic and mesen-
teric arteries were ligated. A loose ligature was
placed around the aorta, proximal to the renal arter-
ies. This ligature was tied off immediately after per-
fusion with fixative had begun. The fixative was al-
(3) lowed to drain from the inferior vena cava. For light
and transmission electron microscopy, tissue
blocks were postfixed in 1% aqueous osmium te-
troxide, further processed in graded ethanol solu-
tions and propylene oxide, and embedded in Epon
812. For light microscopy, l-m thick sections were
stained with toluidine blue and photographed on a
Zeiss photomicroscope. For transmission micros-
copy, two glomeruli and adjacent tubules in each
animal were thin-sectioned, stained on the grid
with uranyl acetate and silver nitrate, and examined
in a Philips 201 electron microscope. Tissue sam-
ples for scanning electron microscopy were impreg-
nated with osmium tetroxide and thiocarbohydra-
zide, embedded in polyethylene glycol for ultra-
planing, critical point dried, and coated with gold-
palladium in a Hummer V sputterer. These tissue
(6) samples were then examined on an AMR 1000A
scanning electron microscope at 20 kV.
Statistical analyses. Statistical analyses were
performed by Student's unpaired, two-tailed t test.
Statistical significance is defined as P < 0.05. All
values are expressed as means SEM.
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Results
Micropuncture studies: Groups 1, 2, and 3. Mean
values for AP, whole kidney GFR, SNGFR, and
the pressures and flows determining glomerular ul-
trafiltration are summarized in Tables 1 and 2. The
average value for urine flow rate (V) for gentamicin-
treated (group 2) animals was slightly higher than it
was for group 1 or for group 3, although these dif-
ferences were not statistically significant. Alterna-
tively, the urine-to-plasma inulin concentration ra-
tio (U/P1) was lower on average in group 2 (185
[SEMI 26, P < 0.001) and group 3 (315 41, P <
0.05) when compared with control (group 1) animals
(412 44). The mean U/Pi, ratio for group 2 was
also significantly lower than it was for group 3 (P <
0.01). Values for whole kidney GFR averaged 1.00
0.04 mi/mm/kidney in control rats (group 1) and
were lower following treatment with either gen-
tamicin or tobramycin, averaging 0.58 0.05 (P <
0.001) and 0.79 0.05 mI/mm/kidney (P <0.05) for
groups 2 and 3, respectively. The mean GFR value
for group 2 was significantly lower than it was in
group 3 (P <0.001). Values for tubule fluid flow rate
(VTF) were significantly lower in gentamicin (group
2) animals, averaging 15.9 1.1 nllmin, when com-
pared with control (group 1) animals (20.6 1.5 nIl
mm, P <0.02). The average value of VTF in group 3,
however, did not differ from group 1 (Table 1). The
mean tubule fluid/plasma inulin concentration ratio,
(TF/P)1, was also significantly lower in group 2 (1.35
0.12) than it was in group 1 (1.75 0.16, P <
0.05) and group 3 (1.94 0.12,P <0.01). Values for
SNGFR, therefore, were also significantly lower in
gentamicin-treated (group 2) animals, averaging
21.7 1.2 nI/mm, when compared both with control
Table 1. Summary of several measures of whole kidney and single nephron functiona
V
pJ/min U/P1,,
GFR
mi/mm
VTF
ni/mm TF/P1
SNGFR
ni/mm
Group 1 (N = 8) 2.5 412 1.00 20.6 1.75 35.7
Group2(N= 9) 3.2 185,d 058b.d 159b 135b,d 217b.d
Group3(N= 10) 2.4 315' 0.79' 17.7 1.94 34.1
Group4(N=6) 2.7 294' 0.78', 16.6e 1.62 26.9'
Groups(N=7) 2.9 289'S" 084 198h 161h 3l6
Group6(N=6) 3.1 368 1.09 20.7 1.69 37.7
a Values are expressed as the means SEM.
b P< 0.05 (group 2 vs. group 1); c (group 3 vs. group 1); d (group 2 vs. group 3); e (group 4 vs. group 1); (group 4 vs. group 2); (group
5 vs. group 6); " (group 5 vs. group 2).
Table 2. Hemodynamic determinants of whole kidney and single nephron functiona
')
mm
Hg
GFR SNGFR
mi/mm ni/mm
PGC
mm
Hg
mm
Hg
CA CE
g/di
"E HE/P
mm Hg
SNFF QA
ni/mm
RA
X1O1°
RE RTA
dynseccm5
Kf
nhI(sec
•mm Hg)
Group 1(N= 8) 111 1.00 35.7 48 37 5.4 8.6 35.8 0.98 0.37 97 2.8 2.1 4.9 0.072
±2 ±0.04 ±1.4 ±1 ±1 ±0.1 ±0.1 ±0.8 ±0.04 ±0.01 ±7 ±0.3 ±0.2 ±0.3 ±0.009
Group2(N=9) 114 058b.d 217b,d 48 36 5.2 80b 318b 088b 0.36 62" 44b,d 34b.d 78b,d 0034b,d
±5 ±0.05 ±1.2 ±1 ±1 ±0.1 ±0.2 ±1.3 ±0.04 ±0.01 ±4 ±0.6 ±0.4 ±0.8 ±0.005
Group3(N= 10)120' 0.79' 34.1 48 36 5.1 8.2 33.4 0.96 0.38 91 3.4 2.3 5.7 0.066
±3 ±0.05 ±2.9 ±1 ±1 ±0.1 ±0.3 ±2.0 ±0.05 ±0.02 ±7 ±0.3 ±0.1 ±0.4 ±0.011
Group4(N=6) 115 078ej 26.9e.f 50 39 5.6 8.5 34.9 0.89' 0.35 79e.t 34 2.7 6.1 0.040'
±4 ±0.04 ±2.4 ±1 ±1 ±0.1 ±0.2 ±1.1 ±0.02 ±0.01 ±7 ±0.5 ±0.3 ±0.8 ±0.004
Group5(N=7) 99 0.84 3l.6 455 35 5.5 8.2 33.5 0.96 92 2.3k l.7 4.0k 0.062h
±4 ±0.06 ±2.1 ±1 ±1 ±0.1 ±0.2 ±1.1 ±0.03 ±0.01 ±6 ±0.2 ±0.2 ±0.4 ±0.008
Group 6(N= 6) 101 1.09 37.7 47 36 5.4 8.4 34.3 0.98 0.38 95 2.2 1.8 4.0 0.074
±4 ±0.08 ±1.2 ±1 ±1 ±0.1 ±0.4 ±2.4 ±0.06 ±0.03 ±4 ±0.2 ±0.1 ±0.2 ±0.006
a Values are expressed as the means ± SEM.
b P< 0.05 (group 2 vs. group 1);' (group 3 vs. group 1); (1 (group 2 vs. group 3); a (group 4 vs. group 1); (group 4 vs. group 2); (group
5 vs. group 6); (group 5 vs. group 2).
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(group 1) animals (35.7 1.4 ni/mm, P <0.001) and
with tobramycin-treated (group 3) animals (34.1
2.9 nI/mm, P <0.001). As shown in Table 2, mean
values for QA were not significantly different in
groups 1 and 3, averaging 97 7 and 91 7 nI/mm.
In group 2 animals, however, QA was significantly
lower, averaging 62 4 nllmin (P <0.001). Values
for SNFF were similar, averaging 0.37 0.01, 0.36
0.01 and 0.38 0.02 in groups 1 through 3, re-
spectively.
As the mean glomerular capillary hydraulic pres-
sure, PGC, and proximal tubule hydraulic pressure
were similar for all groups, the mean glomerular
transcapillary hydraulic pressure difference, zP,
was also similar among these groups (Table 2). In
group 1, P averaged 37 1 mm Hg, similar to the
mean value of HE. This equality of HE and zP de-
notes achievement of filtration pressure equilibri-
um. In group 2 rats, the average value for zP re-
mained very nearly the same as it did in control (36
1 mm Hg). By contrast, values of 11E were re-
duced significantly, relative to group 1, averaging
31.8 1.3 mm Hg (P <0.02). Thus, in 6 of 9 rats in
group 2, the reduction of HE was sufficient to pre-
vent achievement of ifitration pressure equilibrium,
reflected by the mean value for the ratio of HE/P
for all 9 rats being significantly lower than in control
rats, 0.88 0.04 vs. 0.98 0.04 (P < 0.05). In
group 3 rats given tobramycin, filtration pressure
equilibrium was achieved in 7 of 10 rats, and the
mean value of HE/P for the entire group averaged
0.96 0.05, a value not significantly different from
unity.
Although not shown in Table 2, mean values for
PE (14.0 0.7, 15.0 0.8, and 17.0 0.8 mm Hg)
and Pc (8.0 0.6, 8.0 0.8, and 8.0 0.8 mm Hg),
were similar for groups 1, 2, and 3, respectively.
Values for CA were unaffected by either gentamicin
or tobramycin treatment (Table 2). Afferent arteri-
olar resistances (RA) were higher, on average, with
both gentamicin and tobramycin treatment (Table
2). Only for gentamicin-treated (group 2) animals,
however, was the difference significant when com-
pared with group 1 animals, averaging 4.4 0.6 vs.
2.8 0.3 x 1010 dyn•sec.cm (P < 0.005), respec-
tively. The higher average value for RA in tobramy-
cm-treated (group 3) animals was due to the higher
average value for AP, when compared with group 1,
120 3 vs. 111 2 mm Hg (P < 0.05). Efferent
arteriolar resistance, RE, averaged 2.1 0.2 in
group 1 and 3.4 0.4 X 1010 dyn•seccm5 in group 2
(P < 0.005). As expected, because RA and RE were
higher in group 2, total arteriolar resistance, RTA,
was also higher (7.8 0.8 x 1010 dynseccm5) than
in group 1 (4.9 0.3 X 1010 dynsec.cm5, P <
0.005) or group 3 (5.7 0.4 x 1010 dyn.sec.cm5, P
<0.005).
Under conditions of filtration pressure equilibri-
um, as obtained in group 1 and in most animals in
group 3, only a minimum value for the glomerular
capillary ultrafiltration coefficient, K1, may be de-
termined. As shown in Table 2, these minimum val-
ues averaged 0.072 0.009 nIJ(secmm Hg) for
group 1, a value not significantly different from the
mean Kf value for group 3, which averaged 0.066
0.011 nlI(sec.mm Hg). Under conditions of filtration
pressure disequilibrium, however, which obtained
in most animals in group 2, it was possible to calcu-
late unique values for Kf [17]. As shown in Table 2,
mean values for K1 in this group averaged 0.034
0.005 nlI(sec.mmHg), a value approximately 50%
lower than the minimum Kf values calculated in
groups 1 and 3.
Group 4. In group 4 animals given gentamicin
while maintained on a long-term high salt intake,
the mean value for U/P1, was lower when compared
with group 1 animals (P <0.02), and thus, the mean
value for whole kidney GFR was also reduced when
compared with group 1 animals, averaging 0.78
0.04 vs. 1.00 0.04 mI/mm/kidney (P < 0.005)
(Table 1). Nevertheless, group 4 animals showed a
higher mean GFR value than did gentamicin-treated
(group 2) animals maintained on a standard salt in-
take (0.78 0.04 vs. 0.58 0.05 mllmin, P < 0.01).
As with whole kidney GFR, values for SNGFR in
group 4 (26.9 2.4 nI/mm) were lower on average
than they were in group 1 (35.7 1.4 nllmin, P <
0.05) but higher than they were in group 2 (21.7
1.2 nI/mm, P < 0.05). As shown in Table 2, the high
salt intake in group 4 was associated with a higher
average value for QA when compared with water-
drinking animals given the same gentamicin treat-
ment (79 7 vs. 62 4 nI/mm, P < 0.025). Never-
theless, the mean QA value in group 4 was still lower
than in control (group 1) animals. SNFF values in
group 4 were similar, on average, to values in
groups 1 and 2, as shown in Table 2. As in group 2,
the mean value for the ratio HFI1P in group 4 (0.89
0.02) was significantly less than unity. Filtration
pressure disequilibrium was achieved in 5 of the 6
rats in this group, and K1 values averaged 0.040
0.004 nIJ(sec.mm Hg) (Table 2).
Although not shown in Table 2, mean values for
PE (14 1 mm Hg), and Pc (8 1 mm Hg) did not
differ from values in groups 1 or 2. Values for CA
were unaffected by the high salt intake in group 4
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(Table 2). Mean values for RA, RE, and RTA (Table
2) showed a tendency to decrease in group 4 when
compared with group 2 although the differences
were not statistically significant.
Groups 5 and 6. As shown in Table IL, the average
urine flow rate (V) in gentamicin-treated rats main-
tained on oral captopril (group 5) was not statistical-
ly different from the value in animals treated with
captopril alone (group 6). But, the mean U/P1 ratio
in group 5 was significantly lower than it was in
group 6 (P < 0.01), so that the mean value for whole
kidney GFR in group 5 (0.84 0.06 mI/mm) was
lower than it was in group 6 (1.09 0.08 mllmin, P
<0.05). Both GFR values were significantly higher
than the mean GFR value obtained in animals
treated with gentamicin alone (group 2). With cap-
topril treatment in group 5 rats, mean values for
SNGFR and QA were also significantly higher than
they were in group 2, averaging 31.6 2.1 vs. 21.7
1.2 nl/min (P < 0.001) and 92 6 vs. 62 4 nh
mm (P <0.001).
As shown in Table 2, £i averaged 35 1 and 36
1mm Hg, and 11E averaged 33.5 1.1 and 34.3
2.4 mm Hg in groups 5 and 6, respectively. There-
fore, the mean HSP ratios were not statistically
different from unity in either group, denoting
achievement of filtration pressure equilibrium in
each group. Minimum Kf values averaged 0.062
0.008 and 0.074 0.006 nlJ(sec.mm Hg), respective-
ly, in groups 5 and 6. Despite similar gentamicin
treatment, group 5 animals receiving captopril had a
significantly higher average K value than did group
2 rats receiving gentamicin alone (Table 2).
Pc values for group 5 averaged 12 0.5 mm Hg, a
value statistically higher than mean values obtained
in group 2(8.0 0.8 mm Hg, P <0.001) and group 6
(9.0 0.9 mm Hg, P < 0.025). Both RA and RE
(Table 2) were about 50% lower in group 5 than they
were in group 2. Therefore, RTA was also lower in
group 5 than in group 2, averaging 4.0 0.4 vs. 7.8
0.8 X 1010 dynseccm5 (P <0.001).
Morphologic studies. By light and transmission
electron microscopy, glomeruli in all six groups ap-
peared unremarkable. Glomerular capillary walls
showed intact endothelial cells, basement mem-
branes of normal thickness, and epithelial cells with
slender interdigitating foot processes. The size and
distribution of endothelial fenestrae were further
analyzed by scanning electron microscopy. No sig-
nificant differences between animals from different
groups were found when compared with untreated
controls. Occasional capillary loops in gentamicin-
and tobramycin-treated animals revealed segments
of endothelial cells with sparse fenestrae or areas
with smaller sized fenestrae. These findings, how-
ever, were infrequent and difficult to quantitate on
scanning photo micrographs.
Proximal tubules in all animals examined in
groups 2, 4, and 5 (Fig. 1) showed marked focal in-
crease in number and size of lysosomes. Character-
istic myeloid figures were evident on ultrastructural
examination. In addition, there was focal loss of
brush border microvilli, with frequent membrane
debris partially filling the lumens of proximal tu-
bules. These changes were limited to S1 and S2 seg-
ments; the straight segment of the proximal con-
voluted tubules (S3), Henle's loops, distal con-
voluted tubules, and collecting ducts appeared
unremarkable except for an occasional focal in-
crease in number of lysosomes. The changes ob-
served in the gentamicin-treated animals given the
high salt diet (group 4) or captopril (group 5) did not
differ qualitatively when compared with the group
receiving gentamicin alone (group 2). Tobramycin-
treated animals (group 3) showed similar brush bor-
der abnormalities and membrane debris in tubules
(see Fig. 1) as was seen in gentamicin-treated rats.
Lysosomes were likewise increased in number in S
and S2 cells in this group of animals. Very large
lysosomes, as often seen in gentamicin-treated ani-
mals, were not evident in this group, however.
The group of animals treated with captopril alone
(group 6) showed no brush border abnormalities,
and no membrane debris was detected in tubules.
Lysosomes were moderately increased in number
(see Fig. 1) when compared with group 1 control
animals. Ultrastructural examination did not show
myeloid profiles in lysosomes as seen in the gen-
tamicin- and tobramycin-treated animals.
Discussion
Aminoglycosides are extremely useful in the
management of severe gram-negative bacterial in-
fections. Their nephrotoxic and ototoxic side ef-
fects have continued, however, to limit their useful-
ness to the clinician. Renal failure with these potent
agents, although relatively uncommon, does occur
and is usually detected only after kidney function
has deteriorated considerably [18].
Generally, the clinical pharmacology of tobramy-
cm is similar to that of gentamicin [19, 20]. Both
aminoglycosides are excreted primarily by the kid-
ney and undergo no detectable metabolic changes
[21]. Both are excreted to a minimal extent in bile
and are retained in patients with renal failure [21].
In some studies, tobramycin exhibited a lesser
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Fig. 1. Profiles of proximal convoluted tubules (S1 and S2 segments) from dUferent experimental groups. a = Control, group 1; b =
gentamicin, group 2; c = tobramycin, group 3; d = gentamicin + sodium chloride, group 4; e = captopril, group 6; f = gentamicin +
captopril, group 5. Note the increase in small lysosomes in group 3 animals (c) and big lysosomes in all gentamicin-treated animals (b, d,
f). Gentamicin and tobramycin administration caused significant brush border alterations as evidenced by the presence of membrane
debris inside tubule lumens (b, c, d). These 1-gm Epon sections were stained with toluidine blue; magnification, x460.
nephrotoxic potential than did gentamicin [2-6]. In comparing the effects of identical doses of gen-
Tobramycin also appears to be less ototoxic than tamicin and tobramycin in the present studies, we
gentamicin [22]. found significantly lower mean values for whole
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kidney GFR and SNGFR with the former anti-
microbial agent. These lower SNGFR values were
the result of marked reductions in initial glomerular
plasma flow rate, QA, and ultrafiltration coefficient,
Kf, findings noted with this drug previously [1]. No
differences in the remaining determinants of
SNGFR (that is, P and CA) were evident between
groups. The lower average QA value observed in
gentamicin-treated rats in the present study was
found to be due to increases in both RA and RE. The
basis for the observed decline in Kf is less clear. Kf
is the product of the hydraulic conductivity (k) of
the glomerular capillary wall and the total surface
area (S) available for filtration. Despite impressive
differences in glomerular function between gen-
tamicin- and tobramycin-treated rats, we were un-
able to detect ultrastructural evidence of glomerular
wall damage in either group, so that an influence on
k or S could not be documented by morphologic
evaluation. In this regard, however, Luft et al [11]
described a decrease in size and number of gb-
merular endothelial fenestrae in rats treated with
gentamicin (20 mg/kg/day) for 4 weeks and sug-
gested that these alterations might lead to a decline
in K by reducing S. Insofar as no such morphologic
abnormalities were evident in the present study, we
are unable to invoke this mechanism to account for
the observed decline in K.
Alternatively, the decline in Kf, as well as the de-
cline in QA and attendant increases in afferent and
efferent arteriolar resistances, RA and RE, are remi-
niscent of the changes brought about in these quan-
tities when angiotensin II levels are increased, ei-
ther endogenously or exogenously [23-25]. Indeed,
contraction of extracellular fluid volume is thought
to occur in response to the polyuria and natriuresis
induced by gentamicin [26], and volume contraction
is a potent stimulus for angiotensin II formation. To
test this hypothesis, the gentamicin-treatment pro-
tocol used in group 2 was repeated in animals that
were also exposed to prolonged high salt intake
(group 4) or chronic oral captopril administration
(group 5), maneuvers aimed at lessening endoge-
nous angiotensin II formation [10]. As shown in
Table 2, both approaches were successful in off-
setting the alterations in SNGFR, Kf, QA, RA, and
RE seen with gentamicin alone (group 2), with cap-
topril being considerably more effective than the
high salt diet. For this reason, GFR and SNGFR
were less adversely affected in group 5 (captopril)
than group 4 (high salt diet). That alterations in diet-
ary salt intake can influence the development of
nephrotoxicity has also been shown by others [7].
Of note, whereas captopril and high salt intake were
both found to be effective in offsetting the changes
in gbomerular function induced by gentamicin alone,
neither method for suppressing angiotensin II for-
mation led to amelioration of the striking morpho-
logic changes seen in proximal tubule epithelia.
The explanation for the greater protective effect
of captopril than high salt diet on glomerular ultra-
filtration in gentamicin-treated rats is not evident
from the findings in the present study. Perhaps cap-
topril exerted a more beneficial effect by virtue of
its ability to enhance accumulation of the potent en-
dogenous renal vasodilator bradykinin [27]. In this
regard, bradykinin has also been shown to stimulate
intrarenal prostaglandin synthesis [28], and the lat-
ter may have contributed to the improved glomeru-
lar hemodynamics seen in captopril-treated rats. Al-
ternatively, captopril may have been more effective
than dietary salt loading in suppressing the accumu-
lation of gentamicin by renal tubule cells. This pos-
sibility seems unlikely in view of our finding that
proximal tubule lesions were as marked in gen-
tamicin-treated rats given captopril as those given
gentamicin alone. Obviously, additional studies are
warranted to evaluate the various possible mecha-
nisms to account for the striking captopril-induced
amelioration of the defect in glomerular ultrafiltra-
tion seen with gentamicin administration.
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